Chronic Lymphocytic Leukemia

Farrukh Awan, MD, discusses the evolution of treating frontline chronic lymphocytic leukemia.

Christine Ryan, MD, discusses the significance of data for ibrutinib plus obinutuzumab in relapsed/refractory chronic lymphocytic leukemia.

Jonathon B. Cohen MD, MS, discusses the management of chronic lymphocytic leukemia with BTK inhibitors, updates in the treatment of acute myeloid leukemia, and how CAR T-cell therapy could improve patient outcomes in diffuse large B-cell lymphoma and mantle cell lymphoma.

Treatment with ibrutinib for at least 5 years showed favorable complete response rates and tolerability in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who were randomized to receive the BTK inhibitor in the phase 3 RESONATE-2 trial.

Fixed-duration treatment with ibrutinib and venetoclax led to deeper and prolonged undetectable minimal residual disease responses vs chlorambucil and obinutuzumab in the frontline treatment of elderly or unfit patients with chronic lymphocytic leukemia, translating to fewer relapses in the first year following treatment cessation.

Zanubrutinib produced a superior progression-free survival benefit compared with ibrutinib in previously treated patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, according to the final PFS analysis of the phase 3 ALPINE trial.

Javier Pinilla-Ibarz, MD, PhD, discusses the benefit of utilizing BTK inhibitors in chronic lymphocytic leukemia.

Jonathon B. Cohen, MD, MS, discusses the adverse effects associated with BTK inhibitors in chronic lymphocytic leukemia.

Jonathon B. Cohen, MD, MS, discusses the evolution of treating patients with additional comorbidities in chronic lymphocytic leukemia.

Javier Pinilla-Ibarz, MD, PhD, discusses the factors that go into choosing the optimal second-line BTK inhibitors for patients with chronic lymphocytic leukemia.

Zanubrutinib elicited significantly higher response rates and survival benefits compared with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma .

In an 8 to 4 vote, the FDA’s Oncologic Drugs Advisory Committee voted that the final overall survival data submitted did not demonstrate a strong enough benefit-risk ratio for duvelisib for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma after at least 2 prior therapies.

The ROR1-targeting bispecific T-cell engager NVG-111 elicited promising responses with a manageable safety profile in patients with relapsed/refractory chronic lymphocytic leukemia or mantle cell lymphoma.

Obinutuzumab, acalabrutinib, and venetoclax following optimal debulking with bendamustine failed to meet the prespecified rate of undetectable minimal residual disease in the peripheral blood at the end of induction treatment in patients with relapsed/refractory chronic lymphocytic leukemia.

Othman Al-Sawaf, MD, discusses the benefit of fixed-duration treatment with obinutuzumab plus venetoclax in chronic lymphocytic leukemia.

The European Commission has approved the fixed-duration, all-oral combination of ibrutinib and venetoclax for the frontline treatment of adult patients with chronic lymphocytic leukemia.

Matthew A. Lunning, DO, FACP, discusses the evolution of BTK inhibitors in chronic lymphocytic leukemia.

Jeff P. Sharman, MD, discusses the meaning of the long-term follow-up data from ELEVATE-TN, the efficacy of acalabrutinib regimens in patients with treatment-naïve chronic lymphocytic leukemia with deletion 17p or TP53 mutations, and factors to consider when adding obinutuzumab to acalabrutinib.

Anthony Mato, MD, MSCE, discusses the factors used to make treatment decisions between BTK inhibitors and venetoclax in chronic lymphocytic leukemia.

Inhye Ahn, MD, physician, discusses choosing between treatment options in chronic lymphocytic leukemia.

Christine Ryan, MD, discusses the objectives for investigating different sequencing options for ibrutinib plus obinutuzumab in relapsed/refractory chronic lymphocytic leukemia.

Mazyar Shadman, MD, MPH, discusses the exploration of MB-106, a third-generation CD20-targeted autologous CAR T-cell therapy, in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.

The FDA has approved a new tablet formulation of acalabrutinib for all current indications, including adult patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, and for those with relapsed or refractory mantle cell lymphoma.

Matthew A. Lunning, DO, FACP, discusses trials evaluating BTK inhibitors in chronic lymphocytic leukemia.

Othman Al-Sawaf, MD, discusses the 5-year follow-up data of the phase 3 CLL14 trial and emphasized the importance of fixed-duration treatments in high-risk patients with chronic lymphocytic leukemia.